TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival

British Journal of Cancer

Volumn 90, Issue 3, 2004, Pages 678-685

  Wang, Y ^a   Helland, A ^a   Holm, R ^a   Skomedal, H ^a   Abeler, V M ^a   Danielsen, H E ^a   Trope C G ^a   Borresen Dale A L ^a   Kristensen, G B ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Ovarian carcinoma; Prognosis; TP53 mutation; TP53 protein accumulation; TP53 tumour suppressor gene

Indexed keywords

DNA; PROTEIN P53;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; EXON; FEMALE; GEL ELECTROPHORESIS; GENE FREQUENCY; GENE MUTATION; GENETICS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MUTATION RATE; NUCLEOTIDE SEQUENCE; OVARY CARCINOMA; OVARY TUMOR; PATHOLOGY; PLOIDY; PREDICTION; PREDICTION AND FORECASTING; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SURVIVAL; TUMOR SUPPRESSOR GENE; TWO DIMENSIONAL GEL ELECTROPHORESIS;

AGED; COHORT STUDIES; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; EXONS; FEMALE; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PLOIDIES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 1542359077     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601537     Document Type: Article

References (42)

1. Auer G, Einhorn N, Nilsson B, Silfversward C, Sjovall K (1996) Biological malignancy grading in early-stage ovarian carcinoma. Acta Oncol 35(Suppl 8): 93-98
2. Bjorge T, Engeland A, Hansen S, Trope CG (1998) Prognosis of patients with ovarian cancer and borderline tumours diagnosed in Norway between 1954 and 1993. Int J Cancer 75: 663-670
3. Borresen AL, Andersen TI, Eyfjord JE, Cornelis RS, Thorlacius S, Borg A, Johansson U, Theillet C, Scherneck S, Hartman S (1995) TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chromosomes Cancer 14: 71-75
4. Borresen-Dale AL (1996) Constant Denaturant Gel Electrophoresis (CDGE) in mutation screening. In Technologies for detection of DNA damage and mutation, Pfeifer GP (ed) pp 267-279. New York: Plenum Press
5. Borresen-Dale AL (2003) TP53 and breast cancer. Hum Mutat 21: 292-300
6. Borresen-Dale AL, Lothe RA, Meling GI, Hainaut P, Rognum TO, Skovlund E (1998) TP53 and long-term prognosis in colorectal cancer: mutations in the L3 zinc-binding domain predict poor survival. Clin Cancer Res 4: 203-210
7. Buller RE, Shahin MS, Holmes RW, Hatterman M, Kirby PA, Sood AK (2001) p53 Mutations and microsatellite instability in ovarian cancer: Yin and yang. Am J Obstet Gynecol 184: 891-902
8. Buttitta F, Marchetti A, Gadducci A, Pellegrini S, Morganti M, Carnicelli V, Cosio S, Gagetti O, Genazzani AR, Bevilacqua G (1997) p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study. Br J Cancer 75: 230-235
9. Dembo AJ, Davy M, Stenwig AE, Berle EJ, Bush RS, Kjorstad K (1990) Prognostic factors in patients with stage I epithelial ovarian cancer. Obstet Gynecol 75: 263-273
10. Fallows S, Price J, Atkinson RJ, Johnston PG, Hickey I, Russell SE (2001) P53 mutation does not affect prognosis in ovarian epithelial malignancies. J Pathol 194: 68-75
11. Geisler JP, Geisler HE, Wiemann MC, Givens SS, Zhou Z, Miller GA (1997) Quantification of p53 in epithelial ovarian cancer. Gynecol Oncol 66: 435-438
12. Hall PA, McKee PH, Menage HD, Dover R, Lane DP (1993) High levels of p53 protein in UV-irradiated normal human skin. Oncogene 8: 203-207
13. Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutations in human cancers. Science 253: 49-53
14. Hsu SM, Raine L, Fanger H (1981) A comparative study of the peroxidase -antiperoxidase method and an avidin - biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies. Am J Clin Pathol 75: 734-738
15. Iacopetta B (2003) TP53 mutation in colorectal cancer. Hum Mutat 21: 271-276
16. Kohler MF, Kerns BJ, Humphrey PA, Marks JR, Bast Jr RC, Berchuck A (1993) Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. Obstet Gynecol 81: 643-650
17. Kupryjanczyk J, Bell DA, Dimeo D, Beauchamp R, Thor AD, Yandell DW (1995) p53 gene analysis of ovarian borderline tumors and stage I carcinomas. Hum Pathol 26: 387-392
18. Kupryjanczyk J, Thor AD, Beauchamp R, Merritt V, Edgerton SM, Bell DA, Yandell DW (1993) p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci USA 90: 4961-4965
19. Leitao MM, Soslow R, Olvera N, Arroyo C, Baergen R, Boyd J (2002) TP53 mutation in early stage sporadic epithelial ovarian carcinoma. Proc Annu Meet Am Soc Clin Oncol J Clin Oncol 21: A818
20. Levine AJ, Momand J, Finlay CA (1991) The p53 tumour suppressor gene. Nature 351: 453-456
21. Marks JR, Davidoff AM, Kerns BJ, Humphrey PA, Pence JC, Dodge RK, Clarke-Pearson DL, Iglehart JD, Bast Jr RC, Berchuck A (1991) Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 51: 2979-2984
22. Marx D, Meden H, Ziemek T, Lenthe T, Kuhn W, Schauer A (1998) Expression of the p53 tumour suppressor gene as a prognostic marker in platinum-treated patients with ovarian cancer. Eur J Cancer 34: 845-850
23. Mazars R, Pujol P, Maudelonde T, Jeanteur P, Theillet C (1991) p53 mutations in ovarian cancer: a late event? Oncogene 6: 1685-1690
24. Meinhold-Heerlein I, Ninci E, Ikenberg H, Brandstetter T, Ihling C, Schwenk I, Straub A, Schmitt B, Bettendorf H, Iggo R, Bauknecht T (2001) Evaluation of methods to detect p53 mutations in ovarian cancer. Oncology 60: 176-188
25. Niwa K, Itoh M, Murase T, Morishita S, Itoh N, Mori H, Tamaya T (1994) Alteration of p53 gene in ovarian carcinoma: clinicopathological correlation and prognostic significance. Br J Cancer 70: 1191-1197
26. Okamoto A, Sameshima Y, Yokoyama S, Terashima Y, Sugimura T, Terada M, Yokota J (1991) Frequent allelic losses and mutations of the p53 gene in human ovarian cancer. Cancer Res 51: 5171-5176
27. Reles A, Wen WH, Schmider A, Gee C, Runnebaum IB, Kilian U, Jones LA, El Naggar A, Minguillon C, Schonborn I, Reich O, Kreienberg R, Lichtenegger W, Press MF (2001) Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res 7: 2984-2997
28. Righetti SC, Della TG, Pilotti S, Menard S, Ottone F, Colnaghi MI, Pierotti MA, Lavarino C, Cornarotti M, Oriana S, Bohm S, Bresciani GL, Spatti G, Zunino F (1996) A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 56: 689-693
29. Rodrigues NR, Rowan A, Smith ME, Kerr IB, Bodmer WF, Gannon JV, Lane DP (1990) p53 mutations in colorectal cancer. Proc Natl Acad Sci USA 87: 7555-7559
30. Schildkraut JM, Halabi S, Bastos E, Marchbanks PA, McDonald JA, Berchuck A (2000) Prognostic factors in early-onset epithelial ovarian cancer: a population-based study. Obstet Gynecol 95: 119-127
31. Shahin MS, Hughes JH, Sood AK, Buller RE (2000) The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma. Cancer 89: 2006-2017
32. Skilling JS, Sood A, Niemann T, Lager DJ, Buller RE (1996) An abundance of p53 null mutations in ovarian carcinoma. Oncogene 13: 117-123
33. Skirnisdottir I, Seidal T, Gerdin E, Sorbe B (2002) The prognostic importance of p53, bcl-2, and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapy. Int J Gynecol Cancer 12: 265-276
34. Smith-Sorensen B, Kaern J, Holm R, Dorum A, Trope C, Borresen-Dale AL (1998) Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status. Br J Cancer 78: 375-381
35. Sood AK, Sorosky JI, Dolan M, Anderson B, Buller RE (1999) Distant metastases in ovarian cancer: association with p53 mutations. Clin Cancer Res 5: 2485-2490
36. Sudbo J, Kildal W, Risberg B, Koppang HS, Danielsen HE, Reith A (2001) DNA content as a prognostic marker in patients with oral leukoplakia. N Engl J Med 344: 1270-1278
37. Suzuki M, Ohwada M, Saga Y, Kohno T, Takei Y, Sato I (2001) Micrometastatic p53-positive cells in the lymph nodes of early stage epithelial ovarian cancer: prognostic significance. Oncology 60: 170-175
38. Sørlie T, Vu P, Johnsen H, Lind GE, Lothe RA, Børresen- Dale A-L (2003) Protocol for mutation screening of the TP53 gene by temperature gel electrophoresis (TTGE). In Methods in Molecular Biology, Methods for Detecting and Characterizing Genetic Alterations. Clifton, UK: Humana Press
39. Valverde JJ, Martin M, Garcia-Asenjo JA, Casado A, Vidart JA, Diaz-Rubio E (2001) Prognostic value of DNA quantification in early epithelial ovarian carcinoma. Obstet Gynecol 97: 409-416
40. Vergote I, De Brabanter J, Fyles A, Bertelsen K, Einhorn N, Sevelda P, Gore ME, Kaern J, Verrelst H, Sjovall K, Timmerman D, Vandewalle J, Van Gramberen M, Trope CG (2001) Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 357: 176-182
41. Vergote IB, Kaern J, Abeler VM, Pettersen EO, De Vos LN, Trope CG (1993) Analysis of prognostic factors in stage I epithelial ovarian carcinoma: importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse. Am J Obstet Gynecol 169: 40-52
42. Wen WH, Reles A, Runnebaum IB, Sullivan-Halley J, Bernstein L, Jones LA, Felix JC, Kreienberg R, El Naggar A, Press MF (1999) p53 mutations and expression in ovarian cancers: correlation with overall survival. Int J Gynecol Pathol 18: 29-41